Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

Oct 30

Written By Matthijs Versteegh

multiple sclerosis

Matthijs Versteegh

Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries

HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead